Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system
Autor: | Lee, Tsung-Ying, Chen, Hsuan-Ying, Chen, Tsai-Yun, Li, Sin-Syue, Fang, Wei-Tse, Wen, Yao-Chun, Lo, Yu-Wen, Ou, Huang-Tz |
---|---|
Zdroj: | The European Journal of Health Economics, 2020 Sep 01. 21(7), 1105-1116. |
Databáze: | JSTOR Journals |
Externí odkaz: |